4.3 Review

Therapeutic potential of IL-27 in multiple sclerosis?

Journal

EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 9, Issue 2, Pages 149-160

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1517/14712590802646936

Keywords

experimental autoimmune encephalomyelitis (EAE); IL-27; inflammation; multiple sclerosis (MS); Th1; Th17

Funding

  1. National Institutes of Health [5RO1NS0467892, 5RO1AI061818]
  2. National Multiple Sclerosis Society [FG1645-A-1]

Ask authors/readers for more resources

Background: Multiple sclerosis (MS) is a debilitating neurological disease, characterized by inflammatory demyelination and axonal degeneration in the CNS. Currently approved therapies are partially effective, however safer and more effective treatments are needed. Objective/methods: To assess the therapeutic potential of the heterodimeric cytokine, IL-27 in MS, based on the current literature. Results/conclusions: IL-27 exerts profound anti-inflammatory effects in several infectious and experimental autoimmune models. In particular, suppressive effects on helper T cells, which are implicated in the pathogenesis of MS, suggest that IL-27 may be therapeutically relevant in MS. However, while exciting discoveries have been made, further work is required particularly in human health and disease, to understand the diverse roles of IL-27 and its therapeutic potential.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available